Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.60 |
| ▸ | THRA | P10827 | 13/20 | 0.60 |
| ▸ | RORC | P51449 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642693 | 0.93 | THRB (0.53) | THRBTHRARORC | |
| SCHEMBL7071647 | 0.92 | THRB (0.62) | THRBTHRARORC | |
| SCHEMBL5276573 | 0.89 | THRB (0.74) | THRBTHRARORC | |
| SCHEMBL5355832 | 0.89 | THRB (0.61) | THRBTHRARORC | |
| SCHEMBL5618343 | 0.88 | THRB (0.60) | THRBTHRARORC | |
| SCHEMBL282637 | 0.87 | THRB (0.54) | THRBTHRARORC | |
| SCHEMBL5281917 | 0.87 | THRA (0.78) | THRBTHRA | |
| SCHEMBL7076989 | 0.84 | THRB (0.73) | THRBTHRARORC | |
| SCHEMBL3886566 | 0.84 | THRB (0.57) | THRBTHRARORC | |
| SCHEMBL7251517 | 0.83 | THRB (0.45) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862450-A2 | Novel compounds | KARO BIO AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1537073-B1 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KAROBIO AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| US-7220752-B2 | Compounds active at the glucocorticoid receptor II | KARO BIO AB (SE) | 2007-05-22 | — | — | US | disclosed |
| EP-1509188-A4 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KAROBIO AB (SE) | 2005-11-23 | — | — | EP | disclosed |
| EP-1537073-A2 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| EP-1509188-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040063781-A1 | Compounds active at the glucocorticoid receptor II | ABBOTT LABORATORIES | 2004-04-01 | — | — | US | disclosed |
| WO-2004007430-A2 | BENZAMIDE OR PHENYLACETAMIDE DERIVATIVES USEFUL AS THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2004-01-22 | — | — | WO | disclosed |
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | KARO BIO AB (SE) | 2003-09-04 | — | — | US | disclosed |
| EP-1000008-B1 | NOVEL THYROID RECEPTOR LIGANDS AND METHOD | KAROBIO AB (SE) | 2003-06-25 | — | — | EP | disclosed |
| EP-1265839-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2002-12-18 | — | — | EP | disclosed |
| US-6492424-B1 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders | KARO BIO AB (SE) | 2002-12-10 | — | — | US | disclosed |
| US-6465687-B1 | SUBSTITUTED 4-HYDROXY-3-ALKYL- OR CYCLOALKYL-PHENOXYBENZENE COMPOUNDS SUCH AS 3,5-DIBROMO-4-(4-HYDROXY-3-ISOPROPYLPHENOXY)BENZOIC ACID, EXPRESSION INHIBITION OF A T3 REGULATED GENE | KARO BIO AB (SE) | 2002-10-15 | — | — | US | disclosed |
| WO-2002043648-A2 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR II | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044120-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR III | KARO BIO AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| EP-1185229-A1 | METHOD OF TREATING HAIR LOSS | UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001047859-A1 | COMPOUNDS ACTIVE AT THE GLUCOCORTICOID RECEPTOR | KARO BIO AB (SE) | 2001-07-05 | — | — | WO | disclosed |
| EP-1102739-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000072811-A1 | METHOD OF TREATING HAIR LOSS | THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER (US) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000007972-A1 | GLUCOCORTICOID AND THYROID HORMONE RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLIC DISORDERS | KARO BIO AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166725-A1 | Compounds active at the glucocorticoid receptor | NR3C1, NR3C2, GPR119 | THRB 167/4885THRA 291/4885RORC 181/4885 |
| US-20040063781-A1 | Compounds active at the glucocorticoid receptor II | NR3C1, MC2R, NR3C2 | THRB 219/4885THRA 244/4885RORC 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.